Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis.

× No keyword cloud information.

17 in total

Review 1. Management of Myelofibrosis-Related Cytopenias.

Authors: Prithviraj Bose; Srdan Verstovsek
Journal: Curr Hematol Malig Rep Date: 2018-06 Impact factor: 3.952

Review 2. JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Authors: Prithviraj Bose; Srdan Verstovsek
Journal: Blood Date: 2017-05-12 Impact factor: 22.113

Review 3. New Concepts of Treatment for Patients with Myelofibrosis.

Authors: Prithviraj Bose; Mansour Alfayez; Srdan Verstovsek
Journal: Curr Treat Options Oncol Date: 2019-01-24

Review 4. SOHO State-of-the-Art Update and Next Questions: MPN.

Authors: Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal: Clin Lymphoma Myeloma Leuk Date: 2018-01

5. The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies.

Authors: Vikas Gupta; Claire Harrison; Elizabeth O Hexner; Haifa Kathrin Al-Ali; Lynda Foltz; Michael Montgomery; William Sun; Prashanth Gopalakrishna; Hagop Kantarjian; Srdan Verstovsek
Journal: Haematologica Date: 2016-09-01 Impact factor: 9.941

6. Short-term administration of JAK2 inhibitors reduces splenomegaly in mouse models of β-thalassemia intermedia and major.

Authors: Carla Casu; Vania Lo Presti; Paraskevi Rea Oikonomidou; Luca Melchiori; Osheiza Abdulmalik; Pedro Ramos; Stefano Rivella
Journal: Haematologica Date: 2017-11-02 Impact factor: 9.941

7. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.

Authors: Prithviraj Bose
Journal: Expert Opin Orphan Drugs Date: 2019-09-24 Impact factor: 0.694

Review 8. JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.

Authors: Andrew T Kuykendall; Rami S Komrokji
Journal: J Immunother Precis Oncol Date: 2021-06-22

Review 9. Ruxolitinib dose management as a key to long-term treatment success.

Authors: Ruben A Mesa; Rami S Komrokji; Srdan Verstovsek
Journal: Int J Hematol Date: 2016-08-27 Impact factor: 2.490

Review 10. SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.

Authors: Prithviraj Bose; Srdan Verstovsek
Journal: Clin Lymphoma Myeloma Leuk Date: 2021-06-23